Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study.

Dementia and geriatric cognitive disorders - 1 Jan 2010

Gold Michael, Alderton Claire, Zvartau-Hind Marina, Egginton Sally, Saunders Ann M, Irizarry Michael, Craft Suzanne, Landreth Gary, Linnamägi Ulla, Sawchak Sharon

Abstract excerpt

BACKGROUND/AIMS: A phase II study of the peroxisome proliferator-activated receptor-γ agonist rosiglitazone extended release (RSG XR) in mild-to-moderate Alzheimer's disease (AD) detected a treatment benefit to cognition in apolipoprotein E(APOE)-ε4-negative subjects. The current phase III study...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cholinesterase Inhibitors
Share to Drug-Related Side Effects and Adverse Reactions

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Indans

Share to Intelligence Tests

Share to Interview, Psychological

Share to Rosiglitazone

Share to Thiazolidinediones

Source

Open in PubMed Open full text

Identifiers

PMID: 20733306
DOI: 10.1159/000318845
PMCID: PMC3214882

Genes

APOE

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-20733306-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: results from a randomized, double-blind, placebo-controlled phase III study.PMID 20733306Read ↗

Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease.Semantic proximity Read ↗

The Role of Statins in the Prevention and Management of Alzheimer’s Disease: A Focused ReviewSemantic proximity Read ↗

Rosiglitazone rescues memory impairment in Alzheimer's transgenic mice: mechanisms involving a reduced amyloid and tau pathology.Semantic proximity Read ↗

Rexinoids as Therapeutics for Alzheimer's Disease: Role of APOESemantic proximity Read ↗

Omega-3 supplementation in mild to moderate Alzheimer's disease: effects on neuropsychiatric symptoms.Semantic proximity Read ↗

The emerging role of bexarotene in the treatment of Alzheimer&rsquo;s disease: current evidenceSemantic proximity Read ↗

The effects of rasagiline on cerebral glucose metabolism, cognition, and tau in a double-blind, placebo-controlled Phase II clinical trial in Alzheimer’s dementiaSemantic proximity Read ↗

PPARgamma agonists rescue increased phosphorylation of FGF14 at S226 in the Tg2576 mouse model of Alzheimer's disease.Semantic proximity Read ↗

Effect of <i>APOE</i> genotype status on targeted clinical trials outcomes and efficiency in dementia and mild cognitive impairment resulting from Alzheimer's diseaseSemantic proximity Read ↗

Metrifonate treatment of AD: influence of APOE genotype.Semantic proximity Read ↗

Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist.Semantic proximity Read ↗

APOE-ɛ4 Carrier Status and Donepezil Response in Patients with Alzheimer's Disease.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.